-
Cell: Completely eliminate the tumor! Inhibition of this protein can greatly enhance the effectiveness of immunotherapy.
Time of Update: 2020-09-02
Colonna and lead author, postdoctoral researcher Dr Martina Molgora, realized that the same immune cells, called macrophages, were found in tumors, producing TREM2 in tumors and promoting an environment that inhibits T-cell activity.
-
TCGA Cancer Clinical Data Resources provides a comprehensive --- the field of cancer research!
Time of Update: 2020-09-02
Table 5 compares the results of each type of cancer study from the first two TSS for highly invasive tumors such as #1 GBM, with the first two TSS patients making OS, PFI, and DSS similar to other TSS, because too few events are difficult to analyze and do not recommend DFI as an endpoint.
-
HNCDB - a powerful database platform for head and neck tumors.
Time of Update: 2020-09-02
Therefore, a research team from Sun Yat-sen University Cancer Prevention and Control Center in China has constructed HNCDB, a database of head and neck cancer, which is constructed by integrating the document text mining of PubMed abstracts and collecting high-volume gene expression data of HNC from geo and TCGA databases, and manually organizing a large number of texts to collect reliable information about HNC-related genes and drugs.
-
The Chinese Physicians Association's Multidisciplinary Committee on Oncology is about to be established.
Time of Update: 2020-08-29
Wang Jie said, at the same time, on this platform, the training of multidisciplinary concept, multi-disciplinary precision diagnosis and treatment ability of young doctors, to assist the weak medical resources in the region to form MDT expert team, and with higher hospitals to establish MDT complex, to provide patients with a "one-stop" service; Finally, improve the cure rate and quality of life of cancer patients.
-
JCEM: Distant metastasis of differentiated thyroid cancer in children and adolescents.
Time of Update: 2020-08-29
outcome indicators for the study were clinical responses to radioactive iodine (RAI) treatment assessed in the American Thyroid Association (ATA) guidelines for adult DTC and RECIST standards.
researchers assessed risk factors associated with non-distant transfer survival (DMFS).
-
The world's first BCMA targeted therapy! GlaxoSmithKlynte (Belantamab mafodotin) has been approved for listing by the FDA!
Time of Update: 2020-08-28
!--Webeditor:page title"--August 06, 2020 // -- GlaxoSmithKill (GSK) recently announced that the U.S. Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin, GSK2857916), a drug Antibody drug concatenation (ADC), which targets B-cell mature antigens (BCMA), is used as a single-drug therapy to treat adult patients with recurrent or recurrent multiple myeloma (MM) who have previously received at least 4 therapies, including an anti-CD38 antibody, a protease inhibitor, and an immunomodant.
-
First-line immunotherapy for lung cancer! Synda Bio/Lilly Daberschu ® treatment of non-squamous non-small cell lung cancer Phase III clinical success!
Time of Update: 2020-08-27
ORIENT-11 is a randomized, double-blind, Phase III controlled clinical study that compared Daberschu ®or placebo combined force bitai® and platinum for advanced or recurrent non-scaly NSCLC first-line therapy without EGFR-sensitive mutations or ALK gene rearring.
-
Three-negative breast cancer (TNBC) first-line treatment! Roche Tecentriq (Tesanci) - Clinical failure of Chemotherapy Phase III!
Time of Update: 2020-08-27
August 07, 2020 // -- Roche recently released the latest results of a Phase III Impassion 131 study evaluating anti-PD-L1 therapy Tecentriq (Tezolizumab, atezolizumab, atezolizumab) combined chemotherapy (yew alcohol) for the first-line treatment of metastatic tri-negative breast cancer (TNBC).
-
Non-scale lung cancer immunotherapy! Ono Pharmaceutical Opdivo and Beva monotherapy combination III success: significantly extended progression-free survival.
Time of Update: 2020-08-27
!--ewebeditor:page title"--August 07, 2020 // -- Ono Pharmaceuticals recently announced anti-PD-1 therapy Opdivo (Odyvo, generic name: ni Positive topline results from phase III clinical study (ONO-4538-52/TASUKI-52) for the treatment of non-squamous non-small cell lung cancer (NSq NSCLC).
-
Malignant thoracic mesothelioma (MPM) has made significant progress in 15 years! Opdivo-Yervoy immune portfolio first-line therapy significantly extends total survival!
Time of Update: 2020-08-27
!--ewebeditor:page title"--August 09, 2020 // -- Pershing Meishiguibao (BMS) recently announced the evaluation of anti-PD-1 therapy Opdivo (Odivo, generic name: nivolumab) , Navoliu monotherapy) combined anti-CTLA-4 therapy Yervoy (ipilimumab, eplimma) first-line treatment of malignant pleural mesothelioma (MPM) key Phase III CheckMate-743 study total survival (OS) data.
-
Direct electrical stimulation in surgery studies the neural structure of the interaction between motion and language.
Time of Update: 2020-08-26
stimulates the inner hemisphere of the brain, the junction of the auxiliary motor area and the pre-exercise area, and the SMA can cause speech to stop, speech hesitation, or slow down, earlier than the patient's upper limb movement disorder.
-
Compared to chemotherapy, Navoliu monoantigen combined with ipimus was used in patients with previously untreated malignant thoracic mesothelioma to show long-lasting survival benefits.
Time of Update: 2020-08-26
On August 8, 2020, Pershing Meishiguibao announced today that a Phase III clinical study called CheckMate-743 confirmed that The combined Ipimu monotherapy of Navulyu monoin injections significantly improved the overall survival (OS) of patients with previously untreated, non-removable malignant thymus mesothelioma.
-
HER3 targets new ADC drugs! 13th Total/AstraZeneau Latest Collaboration: Patritumab deruxtecan and Tagrisso for the Treatment of Lung Cancer!
Time of Update: 2020-08-26
August 10, 2020 // -- Daiichi Sankyo has announced that it is working with AstraZeneca to enter a clinical trial to evaluate patritumab deruxtecan (U3-1402) in cooperation with Tagrisso (Terisha, generic name: osimertinib, Ohitinib) for patients with advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations.
-
Domestic PD-L1 antibodies! Keystone Pharmaceutical CS1001 first-line treatment iv stage NON-small cell lung cancer Phase III clinical success, to submit a listing application!
Time of Update: 2020-08-26
August 10, 2020 // -- Keystone Pharmaceuticals recently announced the evaluation of anti-PD-L1 monoantigenic CS1001 injection (hereinafter referred to as "CS1001") combined chemotherapy first-line treatment of stage IV non-small cell lung cancer Phase III clinical trial CS1001-302 in patients with NSCLC, in the planned mid-term analysis, was evaluated by the Independent Data Monitoring Committee (iDMC) and reached the preset main research endpoint, the results were statistically significant and clinically significant.
-
Internal therapy for gliomas under the guidance of molecular division.
Time of Update: 2020-08-25
And another study on the high-risk low-level gliomas of tamothamine synchronous chemotherapy also showed that, on the basis of radiotherapy, oral use of tamomin was also improved for patient survival, with a three-year OS rate of 73.1%, a significant difference compared to historical control values, with a p.01, 3-year PFS rate of 59.2%.
-
Nature Communications: New non-invasing tests can detect tumors four years earlier.
Time of Update: 2020-08-24
, the classification model could detect tumors as early as four years in advance, with sensitivity of about 95%, among subjects who were healthy at the time of blood sample collection and later diagnosed with tumors.
-
Blood: AFM13 United Pym monotherapy recurrent/incurable Hodgkin's lymphoma.
Time of Update: 2020-08-24
Center point: AFM13 is a dual-specific terephthal congenital cell bridge that activates NK cells and macrophages via CD16A to target CD30-plus lymphoma cells; Summary: In recurrent/incurable Hodgkin's lymphoma (R/R HL), immunotherapy (e.g. PD-1 inhibitor Pymmama) has shown the efficacy of monotherapy and plays an increasingly important role in treatment.
-
Lancet oncol: Olapali united with Durvalumab to treat metastatic breast cancer that carries a BRCA embryo mutation.
Time of Update: 2020-08-24
this paper reports on the efficacy and safety of the breast cancer cohort, the Olapali combined PD-L1 inhibitor durvalumab, in patients with metastatic breast cancer carrying the BRCA1 mutation or BRCA2 mutation.
summary: Olapali combined durvalumab showed similar anti-tumor activity and safety observed in previous single-drug treatments.
-
Clin Cancer Res: The efficacy and safety of ROCK-AKT dual inhibitor AT13148 for the treatment of solid tumors.
Time of Update: 2020-08-24
most common side effects are fatigue, nausea, headaches and low blood pressure.
180 mg dose, the average Cmax and APC were 400 nmol/L and 13,000 nmol/L/hour, respectively; conclusion: AT13148 is the first double-effective ROCK-AKT inhibitor to be studied for the treatment of solid tumors.
-
NEJM: Necrotoid migrating erythema-case reports associated with glycoglycosinoma.
Time of Update: 2020-08-24
The patient, a 48-year-old man, went to the dermatology department in February for an itchy rash that began in the genital area and gradually affected the torso, hands and legs.
the patient under far-end pancreatic excision, and pathological examination confirmed the diagnosis of glycoglycosmosis.
